EGF Theramed Announces Change of CFO and Director

VANCOUVER, BC / ACCESSWIRE / February 5, 2020 / EGF THERAMED HEALTH CORP. (CSE:TMED)(OTCQB:EVAHF) (the “Company) has appointed Usama Chaudhry as CFO and Director of the company. Mr. Chaudhry is an experienced businessman who sits on a number of public company boards and specializes in executive management services, including corporate development, investor relations, financial reporting, company filings, budgeting and overseeing corporate governance, while achieving company objectives and maintaining internal cost controls.

Mr. Manji has have resigned as Chief Financial officer and Director of EGF Theramed Health Corp. The company thanks Mr. Manji for his contributions to the company and wishes him well in their future endeavors.

For more information please contact:

EGF THERAMED HEALTH CORP.
Contact: David Bentil, CEO
Email theramedhealthcorp@gmail.com
Telephone: (778) 559-3939
Website http://www.theramedhealthcorp.com
CSE Micro-site: http://thecse.com/en/listings/technology/Theramed-Health-Corporation
US OTC Markets (OTCQB): http://www.otcmarkets.com/stock/EVAHF/news

About EGF THERAMED HEALTH CORP. (CSE: TMED, OTCQB: EVAHF)

EGF Theramed Health Corp. is a technology company focused in the healthcare and life sciences sector to develop a personalized healthcare system. The company through its subsidiaries has assets and technologies involved in extracting and purifying botanical extracts, creating formulations, and with its medical device technology monitoring capabilities. EGF Theramed’s unique combination of technologies may allow it to be the first to be able to offer a complete quality assured vertically integrated “Natural Products and Herbal Health System” for monitoring, dosing, and recording the effects of natural products on your cardiovascular system.

Disclaimers

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, https://thecse.com/en/listings/technology/egf-theramed-health-corp, and http://www.otcmarkets.com/stock/EVAHF/filings. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), or any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. The Company does not undertake to update this news release unless required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

SOURCE: EGF Theramed Health Corp.

View source version on accesswire.com:
https://www.accesswire.com/575381/EGF-Theramed-Announces-Change-of-CFO-and-Director

Staff

Recent Posts

Health Care AI Initiative Launched by Paragon Health Institute

New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…

29 minutes ago

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…

29 minutes ago

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

3 hours ago

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

4 hours ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

18 hours ago